Clinical trial
A Study To Evaluate Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Satralizumab In Patients With Generalized Myasthenia Gravis
A Study To Evaluate Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Satralizumab In Patients With Generalized Myasthenia Gravis
ClinicalTrials.gov ID: NCT04963270
Sponsor: Hoffmann-La Roche
Information provided by: Hoffmann-La Roche (Responsible Party)
Last Update Posted: 2023-09-07
Brief Summary:
This study will evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of satralizumab compared with placebo in participants with generalized myasthenia gravis (gMG).
OFFICIAL TITLE
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study To Evaluate Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Satralizumab In Patients With Generalized Myasthenia Gravis
INTERVENTION / TREATMENT
Drug: Satralizumab
Other: Placebo
| Category | Value |
|---|---|
| Study Start (Estimated) | 2021-10-19 |
| Primary Completion (Estimated) | 2024-01-31 |
| Study Completion | 2025-12-30 |
| Enrollment (Estimated) | 185 |
| Study Type | Interventional |
| Phase | Phase 3 |
| Other Study ID Numbers | WN42636 |